Onizuka H, Fukuda H.
Associations between income changes and the risk of herpes zoster: LIFE Study.
Social Science & Medicine 2023; 328: 115981.
Ishiguro C, Mimura W, Uemura Y, Maeda M, Murata F, Fukuda H.
Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study
Open Forum Infectious Diseases 2023; 10(7): ofad274.
Fukuda H, Maeda M, Murata F.
Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS Study.
Vaccine 2023; 41(23): 3556-3563.
Kawabata J, Fukuda H.
Effects of a financial incentive scheme for dementia care on medical and long-term care expenditures: A propensity score-matched analysis using LIFE Study data.
Plos One 2023; 18(3): e0282965.
Narii N, Kitamura T, Komukai S, Zha L, Komatsu M, Murata F, Maeda M, Kiyohara K, Sobue T, Fukuda H.
Association of pneumococcal vaccination with cardiovascular diseases in older adults: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) Study.
Vaccine 2023; 41(13): 2307-2313.
Nakatsuka K, Ono R, Murata S, Akisue T, Fukuda H.
Claimed-based frailty index in Japanese older adults: a cohort study using LIFE Study.
Journal of Epidemiology 2024; 34(3):112-118.
Murata F, Maeda M, Fukuda H.
Association between metabolic syndrome and participation in colorectal cancer screening in Japan: A retrospective cohort analysis using LIFE Study data.
Cancer Epidemiology 2023; 83: 102335.
Fukuda H, Murata F, Azuma S, Fujimoto M, Kudo S, Kobayashi Y, Saho K, Nakahara K, Ono R.
Development of a Data Platform for Monitoring Personal Health Records in Japan: The Sustaining Health by Integrating Next-generation Ecosystems (SHINE) Study.
Plos One 2023; 18(2): e0281512.
Mimura W, Ishiguro C, Maeda M, Murata F, Fukuda H.
Effectiveness of a third dose of COVID-19 mRNA vaccine during the Omicron BA.1- and BA.2-predominant periods in Japan: The VENUS Study.
Open Forum Infectious Diseases 2022; 9(12): ofac636.
Moriyama S, Hieda M, Kisanuki M, Kawano S, Yokoyama T, Fukata M, Kusaba H, Maruyama T, Baba E, AkashiK, Fukuda H.
Both new-onset and pre-existing hypertension are favorable indicators of clinical outcomes in patients treated with vascular endothelial growth factor inhibitors.
Circulation Journal 2024; 88(2):217-225.